Iterum Therapeutics announces partnership for commercialization services

Iterum Therapeutics (ITRM) reported that it entered into a Product Commercialization Agreement with EVERSANA Life Science Services for the commercialization of the Company’s approved product, ORLYNVAHTM. Pursuant to the Agreement, EVERSANA will provide sales and commercial operations services to the Company in the United States, as well as deliver marketing, logistics, channel management, regulatory, medical affairs and other services related to the commercialization of ORLYNVAHTM in the United States. “We will activate the strength and depth of our fully integrated commercialization operation to successfully bring ORLYNVAH to market in the U.S,” said Jim Lang, EVERSANA’s Chief Executive Officer. “We share Iterum’s vision, mission and commitment to urgently helping patients and providers get access to this much needed treatment.”